Clinical trial · Observational
Prostate Cancer Screening in Men With Germline BRCA2 Mutations
NCT02154672CI-TRIAL-00049961completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the incidence of prostate cancer in men with the BRCa2 gene mutation as an independent indicator for prostate cancer screening.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- BRCA2 Carriers
- description
- All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
Primary outcomes (1)
- measure
- Number of Prostate Cancer Patients With BRCA2 Mutation Carriers
- timeFrame
- Up to 3 years
- description
- number of patients with a BRCA2 mutation who are diagnosed with prostate cancer
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 30 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * All men ≥30 years of age with at least a ten-year life expectancy * A known BRCA2 mutation * Ability to have an MRI * Able to give informed consent will be approached to participate in the study Exclusion Criteria: * If a man has received or is currently receiving treatment for prostate cancer
References
Publications (0)
Data not yet available
No reference posted for this study.